ANDA 202090, held by Hikma. Sodium Oxybate.
As of Nov 16, 2026, ANDA 202090 (Sodium Oxybate), held by Hikma, was first approved by FDA on Jan 17, 2017, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 17, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Oxybate0.5GM/ML · solution;oral | Sodium Oxybate | Discontinued |
| Jul 8, 2025 | Supplement 10REMS | Approved | |
| Dec 8, 2023 | Supplement 6REMS | Approved | None posted |
| Jan 3, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 3, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 3, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 3, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 3, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 17, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters